专题：Advanced Breast Cancer Therapies

This cluster of papers focuses on the use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as palbociclib, letrozole, ribociclib, and abemaciclib, in the treatment of hormone receptor-positive metastatic breast cancer. The papers cover various aspects including clinical trials, mechanisms of action, therapeutic resistance, combination strategies, and potential biomarkers.
最新文献
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial

article Full Text OpenAlex

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer

article Full Text OpenAlex

Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

article Full Text OpenAlex

Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial

article Full Text OpenAlex

A renaissance in targeting the PI3K/AKT/mTOR pathway

review Full Text OpenAlex

Insights Into Vepdegestrant (ARV‐471): The First‐in‐Class Estrogen Receptor Proteolysis‐Targeting Chimera Approaching Food and Drug Administration Approval for Breast Cancer

article Full Text OpenAlex

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer

article Full Text OpenAlex

Homologous recombination deficiency and hemizygosity drive resistance in breast cancer

article Full Text OpenAlex

Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer

article Full Text OpenAlex

Outcomes of Everolimus Combined with Exemestane in HR-Positive Metastatic Breast Cancer after CDK4/6 Inhibitor Exposure

article Full Text OpenAlex

近5年高被引文献
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

article Full Text OpenAlex 2682 FWCI193.7935

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

article Full Text OpenAlex 2108 FWCI156.2976

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

article Full Text OpenAlex 1221 FWCI91.7969

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

article Full Text OpenAlex 1201 FWCI79.2504

Recent advances in therapeutic strategies for triple-negative breast cancer

article Full Text OpenAlex 961 FWCI62.1321

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

article Full Text OpenAlex 798 FWCI125.7939

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

article Full Text OpenAlex 784 FWCI86.4403

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

article Full Text OpenAlex 764 FWCI81.6444

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

article Full Text OpenAlex 688 FWCI50.0957

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

article Full Text OpenAlex 601 FWCI67.4515